NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) and Phibro Animal Health (NASDAQ:PAHC – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability.
Risk & Volatility
NRx Pharmaceuticals has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.
Institutional & Insider Ownership
4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NRx Pharmaceuticals | $1.23 million | 122.86 | -$28.62 million | ($0.55) | -6.35 |
| Phibro Animal Health | $1.52 billion | 1.02 | $99.72 million | $2.44 | 15.68 |
Phibro Animal Health has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares NRx Pharmaceuticals and Phibro Animal Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NRx Pharmaceuticals | -691.81% | N/A | -63.92% |
| Phibro Animal Health | 6.57% | 37.86% | 9.18% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for NRx Pharmaceuticals and Phibro Animal Health, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NRx Pharmaceuticals | 2 | 0 | 5 | 0 | 2.43 |
| Phibro Animal Health | 0 | 3 | 1 | 0 | 2.25 |
NRx Pharmaceuticals currently has a consensus target price of $34.50, suggesting a potential upside of 888.54%. Phibro Animal Health has a consensus target price of $47.67, suggesting a potential upside of 24.62%. Given NRx Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe NRx Pharmaceuticals is more favorable than Phibro Animal Health.
Summary
Phibro Animal Health beats NRx Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About NRx Pharmaceuticals
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
About Phibro Animal Health
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal’s health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock’s diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
